OTCMKTS:USRM U.S. Stem Cell (USRM) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free USRM Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume511,940 shsMarket Capitalization$70,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsStock AnalysisChartFinancialsHeadlinesSEC Filings Get U.S. Stem Cell alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About U.S. Stem Cell Stock (OTCMKTS:USRM)U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.Read More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. USRM Stock News HeadlinesApril 25, 2024 | msn.comStem cell transplants and survival rates on the rise across all racial and ethnic groupsApril 19, 2024 | msn.comSave a life, register to become a blood stem cell donorApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 19, 2024 | msn.comMarian University gets $1 million grant for nursing and other STEM-related equipmentApril 17, 2024 | wsj.comU.S. Stem Cell Inc.April 12, 2024 | msn.comHow Robin Roberts' Bone Marrow Transplant Led To Her Nephew Becoming Stem Cell DonorApril 11, 2024 | msn.comBlood stem cells unlock clues for helping sepsis patients fight recurring infectionsApril 9, 2024 | dailymail.co.ukEmbryo stem cell breakthroughApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 9, 2024 | msn.comStudy uncovers multiple lineages of stem cells contributing to neuron productionApril 9, 2024 | yahoo.comSister’s stem cell donation allows Bristol woman to get life-changing eye surgeryApril 4, 2024 | msn.comKey mechanism governing bone marrow stem cells opens door to new therapiesApril 1, 2024 | msn.comStudy documents safety, improvements from stem cell therapy after spinal cord injuryMarch 28, 2024 | msn.comAutofluorescence Reveals Clues to Stem Cell DormancyMarch 22, 2024 | msn.comStudy finds outcomes after stem cell transplant in elderly patients with AML have improved since 2000March 19, 2024 | msn.comExamining inflammatory bowel disease after a stem cell transplantMarch 8, 2024 | msn.comLifelike lab-grown skin developed from human stem cellsMarch 8, 2024 | msn.comResearchers develop shortcut to generate brain stem cells for age-related disease researchMarch 8, 2024 | msn.comUnlocking the Healing Potential of Vitamin A in Stem Cell Biology and Wound RepairMarch 7, 2024 | msn.comVitamin A may play a central role in stem cell biology and wound repairMarch 6, 2024 | msn.comExploring the inner workings of stem cells: When location changes the messageMarch 6, 2024 | msn.comCompany Trying to Resurrect a Mammoth Makes a Stem Cell BreakthroughMarch 2, 2024 | msn.comStem Cell Transplant cures California man of HIV & Acute LeukemiaFebruary 28, 2024 | msn.comNHS ‘fast tracks’ new therapy for stem cell patientsFebruary 26, 2024 | msn.comMan 'cured' of HIV and leukaemia after receiving stem cells from donor with rare mutationFebruary 26, 2024 | msn.comRevolutionary stem cell culture method produces full model of human central nervous systemFebruary 26, 2024 | msn.comScientists devise novel strategy to seek and destroy leukemia stem cellsSee More Headlines Receive USRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for U.S. Stem Cell and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2019Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolOTCMKTS:USRM Previous SymbolNASDAQ:BHRT CUSIPN/A CIK1388319 Webwww.us-stemcell.com Phone(954) 835-1500Fax954-845-9976Employees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$80,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / BookN/AMiscellaneous Outstanding Shares661,510,000Free Float550,903,000Market Cap$70,000.00 OptionableNot Optionable BetaN/A Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Michael Tomas (Age 58)CEO, President, CFO & Director Dr. Colleen RobbSenior Compliance OfficerMr. Phil PosaSenior Vice President of U.S. & International SalesMs. Evelyn FloresCorporate ControllerDr. Sergio PinskiMedical Director & Member of Scientific Advisory BoardKey CompetitorsAmarantus BioScienceOTCMKTS:AMBSAdhera TherapeuticsOTCMKTS:ATRXItem 9 LabsOTC:INLBScopus BioPharmaNASDAQ:SCPSBoomerOTCMKTS:BOMHView All Competitors USRM Stock Analysis - Frequently Asked Questions How were U.S. Stem Cell's earnings last quarter? U.S. Stem Cell, Inc. (OTCMKTS:USRM) released its quarterly earnings results on Wednesday, August, 7th. The company reported $0.00 earnings per share for the quarter. The business earned $1.30 million during the quarter. What other stocks do shareholders of U.S. Stem Cell own? Based on aggregate information from My MarketBeat watchlists, some companies that other U.S. Stem Cell investors own include Orion Energy Systems (OESX), Actinium Pharmaceuticals (ATNM), Cleveland BioLabs (CBLI), Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX), Axsome Therapeutics (AXSM) and How do I buy shares of U.S. Stem Cell? Shares of USRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:USRM) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding U.S. Stem Cell, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
